Although Dupuytren’s contracture is characterized by increased transforming growth factor-β1 (TGF-β1) and fibrosis in the palmar fascia, the relationship between TGF-β1 and integrins, which are considered to be related to fibrosis, remains unclear. We investigated the involvement of TGF-β1 and integrins in the pathological palmar fascia of Dupuytren’s contracture. Seven patients underwent partial fasciectomy for treatment of this disease. The nodule and cord were isolated from the fascial tissues of the patients. Control fasciae were obtained from seven patients with carpal tunnel syndrome. Immunohistochemical analysis was performed to detect the fibrosis marker α-smooth muscle actin and integrins in the fascial tissues. The expression of TGF-β1 and integrins was assessed by real-time polymerase chain reaction. The results suggest that nodules may be areas involved in activation of fibrosis in the fascia, associated with increased expression of TGF-β1 and αv integrin. Thus, αv integrin may contribute to fibrosis in Dupuytren’s contracture by activating TGF-β1.
AkhmetshinaAPalumboKDeesC, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nature Commun. 2012, 3: 735.
2.
AnnesJPMungerJSRifkinDB.Making sense of latent TGFbeta activation. J Cell Sci. 2003, 116: 217–24.
3.
BadalamenteMAHurstLC.The biochemistry of Dupuytren’s disease. Hand Clin. 1999, 15: 35–42, v–vi.
4.
BissonMAMcGroutherDAMuderaVGrobbelaarAO.The different characteristics of Dupuytren’s disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg Br. 2003, 28: 351–6.
5.
BurkeFDProudGLawsonIJMcGeochKLMilesJN.An assessment of the effects of exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren’s disease in 97,537 miners. J Hand Surg Eur. 2007, 32: 400–6.
6.
DolmansGHWerkerPMHenniesHC, et al. Wnt signaling and Dupuytren’s disease. New Engl J Med. 2011, 365: 307–17.
7.
GabbianiGRyanGBMajneG.Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971, 27: 549–50.
HendersonNCArnoldTDKatamuraY, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nature Med. 2013, 19: 1617–24.
10.
HurstLCBadalamenteMAHentzVR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. New Engl J Med. 2009, 361: 968–79.
11.
HynesRO.Integrins: a family of cell surface receptors. Cell. 1987, 48: 549–54.
12.
HynesRO.Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992, 69: 11–25.
13.
HynesRO.Genetic analyses of cell-matrix interactions in development. Current Opin Genet Dev. 1994, 4: 569–74.
14.
ItoKMorimotoJKiharaA, et al. Integrin α9 on lymphatic endothelial cells regulates lymphocyte egress. Proc Natl Acad Sci USA. 2014, 111: 3080–5.
15.
KalluriRNeilsonEG.Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003, 112: 1776–84.
16.
KanayamaMKurotakiDMorimotoJ, et al. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol. 2009, 182: 8015–25.
17.
KetchumLD.The rationale for treating the nodule in Dupuytren’s disease. Plast Reconstr Surg. Glob Open. 2014, 2: e278.
18.
KitamuraHCambierSSomanathS, et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest. 2011, 121: 2863–75.
19.
KloenP.New insights in the development of Dupuytren’s contracture: a review. Br J Plast Surg. 1999, 52: 629–35.
20.
LeeJMDedharSKalluriRThompsonEW.The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006, 172: 973–81.
21.
LiuY.New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010, 21: 212–22.
22.
LuckJV. Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. 1959, 41-A: 635–64.
23.
MagroGLanzafameSMicaliG.Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren’s disease. Acta Histochem. 1995, 97: 229–33.
24.
MeekRMMcLellanSCrossanJF.Dupuytren’s disease. A model for the mechanism of fibrosis and its modulation by steroids. J Bone Joint Surg Br. 1999, 81: 732–8.
25.
MungerJSHuangXKawakatsuH, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999, 96: 319–28.
26.
ScheragaRGThannickalVJ.Wnt/β-catenin and transforming growth factor-β signaling in pulmonary fibrosis. A case for antagonistic pleiotropy?Am J Respir Crit Care Med. 2014, 190: 129–31.
27.
ShiMZhuJWangR, et al. Latent TGF-β structure and activation. Nature. 2011, 474: 343–9.
28.
ShihBWijeratneDArmstrongDJLindauTDayPBayatA.Identification of biomarkers in Dupuytren’s disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg. 2009, 34: 124–36.
29.
TubianaR.Evaluation of deformities in Dupuytren’s disease. Ann Chir Main. 1986, 5: 5–11.
